- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
International Journal of Inflammation
Volume 2014 (2014), Article ID 247503, 6 pages
Interleukin-17A Exacerbates Ferric Chloride-Induced Arterial Thrombosis in Rat Carotid Artery
1Department of Pharmacy, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy
2Department of Pharmaceutical and Biomedical Sciences, University of Salerno, Via Ponte Don Melillo, Fisciano, 84084 Salerno, Italy
3William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK
Received 29 January 2014; Accepted 11 March 2014; Published 3 April 2014
Academic Editor: Vincenzo Brancaleone
Copyright © 2014 Francesco Maione et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Interleukin-17A (IL-17A), the most widely studied member of the IL-17 cytokine family, is a cytokine which emerged to be critical for host defense as well as in the pathogenesis of autoimmune disorders. Moreover, IL-17A is involved in the pathogenesis of cardiovascular diseases, such as atherosclerosis and acute coronary syndrome and in the cardiovascular risk associated with systemic immunological disorders. Consistent with this, we have recently shown that IL-17A increases human and murine platelet response to ADP. In this study we expanded our previous observation and we describe for the first time an in vivo prothrombotic effect of the cytokine. Our results show that IL-17A is synergic with a low FeCl3 concentration in inducing carotid thrombus in rats and suggest that the effect is likely related to a downregulation of CD39 vascular expression and hydrolyzing activity. Our findings indicate that IL-17A might be an important molecule at the interface between hemostasis and inflammation.
“This paper is dedicated to the memory of Professor Alfredo Colonna”
Increasing experimental and clinical evidence show that thrombosis and atherosclerosis might be closely associated with an inflammatory reaction . Inflammation decreases the activity of natural anticoagulant mechanisms, initiates clotting, and impairs the fibrinolytic system. Indeed, proinflammatory molecules are involved in the activation and migration of leukocytes to sites of vascular injury and inflammation and may contribute to the release by activated cells of prothrombotic factors which, in turn, may activate platelets and other cell types [2, 3].
Recently, much attention has been driven on haemostatic disorders observed in subjects affected by immunological chronic inflammation, such as rheumatoid arthritis (RA), multiple sclerosis (MS), and inflammatory bowel disease (IBD) that may represent the cause of the increased cardiovascular risk observed in these pathologies [4–6]. Multiple factors may be implicated. Circulating cytokines and recruited inflammatory cells could cause endothelial activation and dysfunction leading toward a prothrombotic state [7, 8].
Interleukin-17A (IL-17A) is the most widely studied member of the IL-17 cytokine family. It is mainly produced by T-helper (Th)-17 lymphocytes, and also by natural killer T (NKT) cells, γδ T cells (γδ-17), cytotoxic CD8+ T cells (Tc17), and neutrophils [9–11]. IL-17A is a proinflammatory cytokine , highly produced in patients with chronic inflammatory diseases, such as RA, MS, and IBD [13–15]. IL-17A is also involved in atherosclerosis ; furthermore, in humans a positive correlation has also been found between circulating IL-17A levels and acute coronary syndrome [17, 18]. These findings have suggested that IL-17A might play a role in the cardiovascular risk associated with systemic immunological disorders. Recently, in the attempt of finding a link between inflammatory markers and endothelial dysfunction, Marder et al.  demonstrated that IL-17A is an inflammatory marker that could be positively correlated with markers of impaired vascular function in subjects affected by rheumatoid arthritis. Consistent with this, it has also been shown that, on HUVEC, IL-17A reduces CD39 mRNA expression and synergistically with tumour necrosis factor α (TNFα) it is able to induce tissue factor (TF) expression and to downregulate thrombomodulin expression . It is known that arterial thrombosis is primarily caused by platelet adhesion to the damaged vessel and activation . Following activation, endothelium loses its antithrombotic properties and platelets may become activated . Thus, IL-17A could activate endothelial cells toward a prothrombotic state; however, up to now there is no in vivo evidence for this. We have recently demonstrated that IL-17A increases human and murine platelet response to adenosine-5′-diphosphate (ADP). In vitro this effect is associated with an increased exposition of P-selectin on platelet surface . Since platelets are primary involved in arterial thrombus formation  and an increased platelet reactivity has been found associated with several systemic immunological disorders where also IL-17A is involved [6, 7, 23], here we sought to investigate the effect of IL-17A on in vivo arterial thrombus formation.
2. Materials and Methods
2.1. Ferric Chloride-Induced Thrombosis
Male Wistar rats (300–350 g; Harlan Nossan, Correzzana, MI, Italy) were used for all experiments. Animals were kept under standard conditions with food ad libitum and maintained in a 12 h/12 h light/dark cycle at °C. All the in vivo procedures were in accordance with the Italian legislative decree (D.L.) number 116 of January 27, 1992, and associates guidelines in the European Communities Council Directive of November 24, 1986 (8676097ECC). All efforts were made to minimize animal suffering and to reduce their number.
Rats were anaesthetized with urethane (10% wt/v; 10 mL/kg ip.) and placed on a surgical table. An arterial thrombus was induced by FeCl3 application onto the surface of the right carotid artery, as described by Kurz et al. . The effect of topical application of IL-17A was also evaluated. In brief, following surgery, a piece of filter paper (Whatman n°1, 3 × 5 mm) soaked in 10 μL of a solution of FeCl3 (5%) or in recombinant mouse IL-17A (100 μg/mL in HCl 4 mM, R&D System, Abingdon, UK) was applied onto the external surface of the right carotid artery for 30 minutes. Afterward the paper was removed and the vessel was left in situ for 60 minutes, to enable thrombus formation. In another set of experiments, an IL-17A (100 μg/mL), or vehicle (HCl 4 mM), soaked filter paper was applied on the vessel for 30 minutes before applying FeCl3 (5%), as described above. At the end of 60-minute period, a piece of about 2 cm in length of the right carotid artery (and its contralateral) was excised and weighed. Thrombus size was evaluated by the difference in weight between the treated vessel and its contralateral.
2.2. Morphological Analysis
In another group of animals, the experiment was performed as described above and a segment (2 cm) of each treated vessel was excised, rinsed in saline to remove the blood excess, and then fixed in formalin (4% v/v; Carlo Erba, Italy) for 24 hours. Samples were processed and embedded in paraffin. Sections (10 μm thick) were then stained with haematoxylin and eosin (Carlo Erba, Italy) in order to be morphologically analyzed. In all cases, a minimum of 5 sections per animal were analysed by using a standard light microscope (×5 and ×10 objective). Images were taken by a Leica DFC320 video camera (Leica, Milan, Italy) connected to a Leica DM RB microscope using the Leica Application Suite software V2.4.0.
2.3. Western Blot Analysis of CD39
In subsets of experiments, following local treatment with IL-17A or with its vehicle (HCl 4 mM) for 30 minutes, as described above, CD39 expression was evaluated on carotid section homogenates by Western blot analysis. For this purpose, following local treatment, carotids were immediately frozen in liquid nitrogen before being stored at −80°C. On the day of analysis, tissues were homogenized using liquid nitrogen in the following lysis buffer: Tris-HCl pH 7.5, 50 mM; NaCl, 150 mM; sodium orthovanadate, 1 mM; β glycerophosphate, 20 mM; EDTA, 2 mM; PMSF 1 mM; leupeptin, 5 μg/mL; aprotinin, 5 μg/mL; pepstatin, 5 μg/mL. Protein concentration was determined by the Bio-Rad protein assay kit (Bio-Rad, Italy). Protein samples (35 μg) were subjected to electrophoresis on an SDS 8% polyacrylamide gel and transferred onto a nitrocellulose transfer membrane (Protran, Schleicher & Schuell, Germany). The membranes were saturated by incubation with nonfat dry milk (5% wt/v) in PBS supplemented with 0.1% (v/v) Tween 20 (PBS-T) for 1 h at room temperature and then incubated with a goat monoclonal anti-CD39 antibody (A-16, Santa Cruz, CA) (dilution 1 : 200), overnight at 4°C. Successively, membranes were washed and then incubated with the secondary antibody conjugated with horseradish peroxidase, anti-goat IgG-HRP (dilution 1 : 2000, Dako Denmark), for 2 h at room temperature. Protein bands were detected using the enhanced chemiluminescence (ECL) detection kit and Image Quant 400 GE Healthcare software (GE Healthcare, Italy). Protein bands were quantified using GS 800 imaging densitometer software (Biorad, Italy).
2.4. Enzyme Assay
On carotid section homogenates, ADP hydrolyzing activity was evaluated using a modification of the method described by Saucedo et al. . The reaction medium used to assay ADPase activity contained 120 mM NaCl, 5.0 mM KCl, 60 mM glucose, 5 mM CaCl2, and 50 mM Tris-HCl buffer, pH 7.5 in a final volume of 200 μL. A sample volume of 20 μL (10 μg proteins) was added to the reaction medium and preincubated for 10 minutes at 37°C. The enzyme reaction was then started by the addition of ADP at a final concentration of 2 mM and incubated for 40 minutes at 37°C. Controls were performed by adding deionized H2O to each sample, instead of ADP. The reaction was stopped by the addition of 200 μL of trichloroacetic acid (TCA) 10%. Samples were then centrifuged at 3000 rpm × 10 min. As a measure of ADPase activity, inorganic phosphate (Pi) released was quantified by a colorimetric assay Sensolyte assay kit (AnaSpec) and expressed as nmol Pi released per μg of protein .
2.5. Statistical Analysis
Data were expressed as mean ± S.E. and analysed by one way analysis of variance (ANOVA), followed by Bonferroni’s test for multiple comparisons, or by unpaired two-tailed Student’s t-test when appropriate. In some cases, one-sample t-test was used to evaluate significance against the hypothetical zero value. A value of was taken as significant.
3. Results and Discussion
The increased platelet reactivity, endothelial dysfunction, and atherosclerotic plaques instability are common features of subjects affected by systemic immunological inflammatory diseases and might represent the cause of the increased cardiovascular risk observed in these patients [1, 5, 23]. However, which factors are primarily responsible for predisposing to haemostasis disturbances and to cardiovascular events in chronic autoimmune diseases is still unknown. Recently, IL-17A, which is critically involved in the pathogenesis of autoimmune diseases, has been claimed as a possible candidate to participate in endothelial dysfunction and increased cardiovascular risk [19, 20]. On these bases, our work was aimed at evaluating in vivo the effect of IL-17A in a model of ferric chloride-induced arterial thrombosis. We found that application of FeCl3 (5%) caused an intravascular thrombus of mg (; one-sample t-test) whose mass increased significantly ( mg; . ) when carotid was pretreated with IL-17A (100 μg/mL), 30 minutes before FeCl3 application. Application of IL-17A alone on the external surface of rat carotid artery generated per se a small intravascular thrombus ( mg; ; ) whereas nonsignificant effects were observed after vehicle exposure ( mg; ) (Figure 1).
Morphological analysis of the vessel section evidenced that the luminal surface of carotid sections from control was covered by a continuous endothelium. Moreover the vascular lumen was not characterized by aggregates (Figure 2(a)). Interestingly, sections obtained from IL-17A plus FeCl3 showed an occluding thrombus compared with IL-17A (Figure 2(b)) or FeCl3 (Figure 2(c)) treated carotids. Furthermore, the endothelium appeared damaged and vessel wall thickness extremely reduced (Figure 2(d)).
It is known that arterial thrombosis is primarily caused by platelet adhesion and activation to the damaged vessel . Following activation, endothelium loses its antithrombotic properties and platelets may become activated . The model of FeCl3-induced thrombosis has been shown to involve platelets and several components of haemostasis , including TF .
CD39/ATP diphosphohydrolase (ATPDase) is largely expressed on vascular endothelial cells and by converting ATP and ADP to monophosphate form (AMP) it represents a key modulator of vascular haemostasis and thrombogenesis. The loss of CD39 on activated endothelial cells causes platelet sequestration and TF upregulation, key events for thrombogenesis . Nonetheless, CD39 also may offer protection against myocardial ischemia-reperfusion injury since it promotes ADP degradation and thus favours, in tandem with CD73 (ecto-5′-nucleotidase), adenosine accumulation that represents a cardiovascular protective molecule . It was shown that mice lacking CD39 had vascular features of a prethrombotic state, characterized by fibrin deposition in several vascular beds . Recently, it has been demonstrated that IL-17A reduces CD39 mRNA expression in human endothelial cells in vitro and, at the same time, it increases TF expression . On these bases, and considering that CD39 plays a crucial role in maintaining the endothelium antithrombotic properties, we analysed its expression and its ADP hydrolyzing activity on rat carotid artery following the in vivo exposure to IL-17A. Results obtained show that following the application of IL-17A on carotid surface the expression of CD39 was significantly reduced compared with the application of the only vehicle (HCl, 4 mM) (Figure 3). Concomitantly, ADP hydrolyzing activity was also reduced as demonstrated by a reduced inorganic phosphate production, following incubation with ADP, from IL17A treated carotids compared to vehicle (Figure 4). Thus, through the downregulation of CD39, IL-17A might contribute to priming the vessel for the effect of a minimal FeCl3 concentration.
Our hypothesis would be consistent with the observation that IL-17A does not cause per se an intra-arterial occlusive thrombus, but it would induce those endothelial features peculiar to a prothrombotic state. Indeed, the lack of ADP hydrolysis due to CD39 downregulation on endothelial cells would not be a stimulus for thrombogenesis but, most likely, for the increase of platelet aggregates at the site of vascular injury and this would facilitate the effect of a thrombotic agent.
Our results give for the first time an in vivo evidence for a prothrombotic effect of IL-17A that is likely related to a downregulation of CD39 expression and activity in the vascular system. Accordingly with our previous results that demonstrated in vitro the effects of this cytokine on human and murine platelets , in this study we suggest that this cytokine might be an important molecule at the interface between haemostasis and inflammation. Intriguingly, the mechanistic bases of prothrombotic effect of IL-17A need further investigation.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
This work was supported by the Italian Ministery of Research (MIUR; 2008P9MR7Y PRIN 2008). The authors would like to thank Dr. Antonio Baiano and also Mr Giovanni Esposito and Mr Angelo Russo for animal care and technical assistance.
- J. Frostegard, “Atherosclerosis in patients with autoimmune disorders,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1776–1785, 2005.
- C. Cicala and G. Cirino, “Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk,” Life Sciences, vol. 62, no. 20, pp. 1817–1824, 1998.
- S. Strukova, “Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis,” Frontiers in Bioscience, vol. 11, no. 1, pp. 59–80, 2006.
- J. P. Fägerstam, P. A. Whiss, M. Ström, and R. G. Andersson, “Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease,” Inflammation Research, vol. 49, no. 9, pp. 466–472, 2000.
- A. Mameli, D. Barcellona, and F. Marongiu, “Rheumatoid arthritis and thrombosis,” Clinical and Experimental Rheumatology, vol. 27, no. 5, pp. 846–855, 2009.
- P. A. Mac Mullan, A. J. Peace, A. M. Madigan, A. F. Tedesco, D. Kenny, and G. M. McCarthy, “Platelet hyper-reactivity in active inflammatory arthritis is unique to the adenosine diphosphate pathway: a novel finding and potential therapeutic target,” Rheumatology, vol. 49, no. 2, pp. 240–245, 2009.
- A. T. Nurden, “Platelets, inflammation and tissue regeneration,” Thrombosis and Haemostasis, vol. 105, supplement 1, pp. S13–S33, 2011.
- B. Engelmann and S. Massberg, “Thrombosis as an intravascular effector of innate immunity,” Nature Reviews Immunology, vol. 13, no. 1, pp. 34–45, 2013.
- F. D'Acquisto, F. Maione, and M. Pederzoli-Ribeil, “From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead?” Biochemical Pharmacology, vol. 79, no. 4, pp. 525–534, 2010.
- R. M. Onishi and S. L. Gaffen, “Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease,” Immunology, vol. 129, no. 3, pp. 311–321, 2010.
- Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae, “Functional specialization of interleukin-17 family members,” Immunity, vol. 34, no. 2, pp. 149–162, 2011.
- F. Maione, N. Paschalidis, N. Mascolo, N. Dufton, M. Perretti, and F. D'Acquisto, “Interleukin 17 sustains rather than induces inflammation,” Biochemical Pharmacology, vol. 77, no. 5, pp. 878–887, 2009.
- X. Q. Chen, Y. C. Yu, H. H. Deng et al., “Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity,” Journal of Clinical Immunology, vol. 30, no. 2, pp. 221–225, 2010.
- J. Leipe, M. Grunke, C. Dechant et al., “Role of Th17 cells in human autoimmune arthritis,” Arthritis & Rheumatism, vol. 62, no. 10, pp. 2876–2885, 2010.
- X.-F. Zhao, H.-F. Pan, H. Yuan et al., “Increased serum interleukin 17 in patients with systemic lupus erythematosus,” Molecular Biology Reports, vol. 37, no. 1, pp. 81–85, 2010.
- E. Smith, K. M. Prasad, M. Butcher et al., “Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice,” Circulation, vol. 121, no. 15, pp. 1746–1755, 2010.
- X. Cheng, X. Yu, Y.-J. Ding et al., “The Th17/Treg imbalance in patients with acute coronary syndrome,” Clinical Immunology, vol. 127, no. 1, pp. 89–97, 2009.
- R. E. Eid, D. A. Rao, J. Zhou et al., “Interleukin-17 and interferon-γ are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells,” Circulation, vol. 119, no. 10, pp. 1424–1432, 2009.
- W. Marder, S. Khalatbari, J. D. Myles et al., “Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1550–1555, 2011.
- A. Hot, V. Lenief, and P. Miossec, “Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells,” Annals of the Rheumatic Diseases, vol. 71, no. 5, pp. 768–776, 2012.
- Z. M. Ruggeri, “Platelet interactions with vessel wall components during thrombogenesis,” Blood Cells, Molecules, and Diseases, vol. 36, no. 2, pp. 145–147, 2006.
- F. Maione, C. Cicala, E. Liverani, N. Mascolo, M. Perretti, and F. D'Acquisto, “IL-17A increases ADP-induced platelet aggregation,” Biochemical and Biophysical Research Communications, vol. 408, no. 4, pp. 658–662, 2011.
- J. Garbaraviciene, S. Diehl, D. Varwig et al., “Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis,” Experimental Dermatology, vol. 19, no. 8, pp. 736–741, 2010.
- K. D. Kurz, B. W. Main, and G. E. Sandusky, “Rat model of arterial thrombosis induced by ferric chloride,” Thrombosis Research, vol. 60, no. 4, pp. 269–280, 1990.
- E. M. Saucedo, R. S. Pereira, G. M. Barbosa et al., “Enzymes that hydrolyze adenine nucleotides in lymphocytes and platelets of immunosuppressed rats,” Biomedicine & Pharmacotherapy, vol. 64, no. 6, pp. 437–440, 2010.
- K.-M. Chan, D. Delfert, and K. D. Junger, “A direct colorimetric assay for Ca2+-stimulated ATPase activity,” Analytical Biochemistry, vol. 157, no. 2, pp. 375–380, 1986.
- R. J. Broersma, L. W. Kutcher, and E. F. Heminger, “The effect of thrombin inhibition in a rat arterial thrombosis model,” Thrombosis Research, vol. 64, no. 4, pp. 405–412, 1991.
- L. Wang, C. Miller, R. F. Swarthout, M. Rao, N. Mackman, and M. B. Taubman, “Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury,” Blood, vol. 113, no. 3, pp. 705–713, 2009.
- B. Atkinson, K. Dwyer, K. Enjyoji, and S. C. Robson, “Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets,” Blood Cells, Molecules, and Diseases, vol. 36, no. 2, pp. 217–222, 2006.
- M. Cai, Z. M. Huttinger, H. He et al., “Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 6, pp. 927–935, 2011.
- K. Enjyoji, J. Sévigny, Y. Lin et al., “Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation,” Nature Medicine, vol. 5, no. 9, pp. 1010–1017, 1999.